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This editorial refers to ‘Rheumatoid arthritis is associated
with a more severe presentation of acute coronary
syndrome and worse short-term outcome’†, by A¨. Mantel
et al., on page 3413.
Rheumatoid arthritis (RA) is a chronic inflammatory immune-mediated
disease affecting the joints and several other organs. At a global preva-
lence of 0.24%, RA is ranked among the top 15% of diseases causing
disability worldwide.1 RA is associated with an increased risk of cardio-
vascular mortality.2 Furthermore, post mortem3 and coronary CT
angiography data4 indicate a higher prevalence of vulnerable coronary
plaques in patients with RA compared with controls.
The article by Mantel et al.5 in this issue of the journal adds an
important piece to the puzzle, reporting their analysis of a large
contemporary Swedish cohort study using national registries. The
authors found an increased severity of disease at presentation
with an incident acute coronary syndrome (ACS) and worse short-
term all-cause mortality in patients with active RA compared with
matched controls. Interestingly, worse outcome in patients with
RA compared with matched controls persisted after adjustment
for clinical covariates, including the type of ACS. Moreover, among
deaths, the majority of cases had a cardiac cause (89.9% vs. 90.8%).
Of note, all-cause mortality during the first 30 days after an ACSwas
quite high in patients with RA (15.7%) compared with matched con-
trols (10.7%), likely attributable to the surprisingly advanced age in
this cohort (median age 73.8 vs. 73.6 years). Altogether, these find-
ings support the notion of an aggravated course of coronary athero-
sclerosis and ACS in patients with RA.
RA and atherosclerosis as the underlying cause of coronary
artery disease share several features in pathophysiology, genetic pre-
disposition and risk factors, assigning a central role to inflammation.6
Indeed, like RA, atherosclerosis is a chronic inflammatory disease,
specifically of the arterial wall. The dynamic nature of atherosclerosis
is characterised by its evolution in several stages, culminating in plaque
rupture or erosion with ensuing atherothrombosis and vascular
occlusion as the pathophysiological culprit of an ACS.7 Endothelial
activation with expression of cell adhesion molecules occurs in
arteries exposed to disturbed blood flow (i.e. bifurcations) and
pro-inflammatory stimuli. Lipoprotein accumulation and oxidative
modification in the subintimal space propagate expression of cell ad-
hesion molecules and synthesis of pro-inflammatory cytokines and
mediators by endothelial cells which, in turn, result in the recruitment
and activation of various types of circulating leucocytes comprising
neutrophils, monocytes and T cells (predominantly the T helper 1
subset). In the arterial intima, monocytes differentiate into macro-
phages and take up oxidised lipoproteins, converting them into
foam cells. T cells can recognise specific antigens derived from these
modified lipoproteins and orchestrate the immune response. Athero-
sclerotic lesion progression involves migration and proliferation of
vascular smooth muscle cells in the intima and increased turnover
of components of the extracellular matrix (i.e. collagen, elastin and
proteoglycans) bymatrix-degrading enzymes. Advanced stages of ath-
erosclerotic plaques are characterised by a lipid core, an accumulation
of extracellular lipids with cholesterol crystals derived from dead cells
(i.e. foam cells and vascular smoothmuscle cells), sealed on the lumin-
al side by a fibrous cap separating it from circulating blood. These dy-
namic changes in plaque composition culminate in plaque rupture or
erosion, followed by thrombus formation (Figure 1A).
In RA, the inflammatory process in the synovial joint is characterised
by endothelial activation with increased expression of adhesion mole-
cules and infiltration of immune cells comprising T cells of the T helper
1 subset and monocytes. Cartilage degradation in the synovial joint
constitutes the hallmark of RA, mediated by persistently activated
fibroblast-like synoviocytes (FLS) that express matrix-degrading en-
zymes. The combination of degradation products from the extracellu-
lar matrix exposing antigens that can be recognised by T cells and
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Figure 1 (A) Atherosclerosis: lesion progression culminating in atherothrombosis. (B) Rheumatoid arthritis: cartilage degradation in the synovial joint. B, B cell producing antibodies; DC, dendritic
cell; ECM, extracellular matrix; FLS, fibroblast-like synoviocytes; IFN, interferon; IL, interleukin; MHCII-TCR, major histocompatibility complex class II–T cell receptor; Th, T helper cell subset; Treg,
regulatory T cell subset; TNF, tumour necrosis factor; VSMC, vascular smooth muscle cell.
Editorial
3424
inflammatory signals from adjacent cells lead to perpetuation of the in-
flammatory process, including neovascularisation6,8 (Figure 1B).
Increased numbers of a distinct T cell subset—CD4+CD28null
T cells—were detected in blood from patients with an ACS9 as pre-
viously described in patients with RA.10 CD4+CD28null T cells are
characterised by clonal restriction indicative of a reduced repertoire
of antigens recognised by the T cell receptor complex in both
patients with RA10 and patients with an ACS11 when compared
with controls. In line with this, T cells in coronary thrombi aspirated
from the culprit lesion in the epicardial vessel in patients with an
ACS are profoundly clonally restricted compared with circulating
T cells.12 Moreover, circulating T cells from patients with an
ACS12 and patients with RA13 showed clonal restriction when com-
pared with controls. These findings indicate similar autoimmune re-
sponses against specific antigens in ACS and RA alike.
Anti-inflammatory drugs have been used for a long time in patients
with RA and the anti-metabolite methotrexate was associated with a
reduction in cardiovascular events in a recent meta-analysis.14 Among
the novel anti-inflammatory biologic agents used in patients with RA, it
will be interesting to learn about the effects on cardiovascular out-
comes during long-term follow-up of therapeutic inhibition of tumour
necrosis factor-a, inhibition of interleukin-1b or antagonism of the
interleukin-6 receptor, respectively. In turn, in patients with coronary
artery disease, ongoing trials are evaluating the effects on cardiovascu-
lar events of methotrexate and inhibition of interleukin-1b.7,15 It will
be of great interest whether these trials confirm or refute the inflam-
matory hypothesis presented.
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